Sodium-glucose cotransport 2 inhibitors ameliorate the "metabolic stress"
10.3760/cma.j.issn.1000-6699.2018.01.019
- VernacularTitle:钠-葡萄糖共转运蛋白2抑制剂缓解代谢压力
- Author:
Mingfeng XIA
1
;
Xiaoying LI
Author Information
1. 200032 上海,复旦大学附属中山医院内分泌科,复旦大学慢性代谢病研究所
- Keywords:
Sodium-glucose cotransport 2 inhibitor;
Metabolic stress;
Diabetes;
Heart benefit;
Kidney benefit
- From:
Chinese Journal of Endocrinology and Metabolism
2018;34(1):87-90
- CountryChina
- Language:Chinese
-
Abstract:
Energy intake excess in modern society contributes to the abrupt increase of type 2 diabetes. The sodium-glucose cotransport 2 (SGLT-2) inhibitors, a new class of hypoglycemic agents inhibit reabsorption of glucose and excrete excessive energy by the kidney and therefore ameliorate the metabolic stress. The relief of metabolic stress further improves blood glucose, lipid levels, so as blood pressure, insulin resistance and pancreatic β cell function, which would be associated with the protection of cardiovascular diseases and amelioration of renal function.
